hVIVO to develop the world’s first Omicron human challenge model
Open Orphan PLC (AIM:ORPH) Omicron human challenge model
Poolbeg Pharma PLC (AIM:POLB) Project update for AI model of RSV data
OneThree Biotech completes build and optimisation of AI model for RSV data – results to come in H2
Open Orphan PLC (AIM:ORPH) £7.2m RSV human challenge study contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO,
Open Orphan PLC (AIM:ORPH) Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
Open Orphan PLC (AIM:ORPH) Final results
Record revenues and EBITDA-profitability accompanied by significant operational progress
Open Orphan PLC (AIM:ORPH) GBP14.7m influenza contract signed
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
Open Orphan PLC (AIM:ORPH) Completion of Nominated Adviser due diligence
Open Orphan plc (AIM: ORPH), is a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials.
Poolbeg Pharma PLC (AIM:POLB) US patents granted for POLB 001 and POLB 002
Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Open Orphan PLC (AIM:ORPH) Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
Open Orphan PLC (AIM:ORPH) £7.3m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
Poolbeg Pharma PLC (AIM:POLB) GMP manufacturing contract signed
Update on POLB 001 Clinical Development
